These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 34247147)
1. Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Kashima Y; Shibahara D; Suzuki A; Muto K; Kobayashi IS; Plotnick D; Udagawa H; Izumi H; Shibata Y; Tanaka K; Fujii M; Ohashi A; Seki M; Goto K; Tsuchihara K; Suzuki Y; Kobayashi SS Cancer Res; 2021 Sep; 81(18):4835-4848. PubMed ID: 34247147 [TBL] [Abstract][Full Text] [Related]
2. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition. Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274 [TBL] [Abstract][Full Text] [Related]
3. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation. Yang YM; Jang Y; Lee SH; Kang B; Lim SM Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387 [TBL] [Abstract][Full Text] [Related]
5. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789 [TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575 [TBL] [Abstract][Full Text] [Related]
7. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760 [TBL] [Abstract][Full Text] [Related]
8. Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model. Moghal N; Li Q; Stewart EL; Navab R; Mikubo M; D'Arcangelo E; Martins-Filho SN; Raghavan V; Pham NA; Li M; Shepherd FA; Liu G; Tsao MS J Thorac Oncol; 2023 Apr; 18(4):499-515. PubMed ID: 36535627 [TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
10. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482 [TBL] [Abstract][Full Text] [Related]
11. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties. Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535 [TBL] [Abstract][Full Text] [Related]
14. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724 [TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579 [TBL] [Abstract][Full Text] [Related]
16. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074 [TBL] [Abstract][Full Text] [Related]
17. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001 [TBL] [Abstract][Full Text] [Related]
18. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Becker JH; Gao Y; Soucheray M; Pulido I; Kikuchi E; Rodríguez ML; Gandhi R; Lafuente-Sanchis A; Aupí M; Alcácer Fernández-Coronado J; Martín-Martorell P; Cremades A; Galbis-Caravajal JM; Alcácer J; Christensen CL; Simms P; Hess A; Asahina H; Kahle MP; Al-Shahrour F; Borgia JA; Lahoz A; Insa A; Juan O; Jänne PA; Wong KK; Carretero J; Shimamura T Cancer Res; 2019 Sep; 79(17):4439-4452. PubMed ID: 31273063 [TBL] [Abstract][Full Text] [Related]
19. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326 [TBL] [Abstract][Full Text] [Related]